Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases

被引：31

作者：

Martinez, Pablo ^{[1
]}

Mak, Raymond H. ^{[2
,3
]}

Oxnard, Geoffrey R. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 450 Brookline Ave, Boston, MA 02215 USA

[2] Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JAMA ONCOLOGY | 2017年 / 3卷 / 09期

关键词：

D O I：

10.1001/jamaoncol.2017.1047

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CLINICAL QUESTION Is up-front whole-brain radiotherapy required to treat multiple brain metastases from non-small-cell lung cancer when highly active targeted therapies are available? CLINICAL APPLICATION Patients with EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases now have the potential to achieve a prolonged survival. Through use of highly active targeted therapies, whole-brain radiotherapy can be safely postponed, diminishing toxic effects that could impair quality of life.

引用

页码：1274 / 1275

页数：2

共 7 条

[1]

[Anonymous], J CLIN ONCOL S

[2] Treatment of brain metastases in the modern genomic era [J].

Dagogo-Jack, Ibiayi ;

Gill, Corey M. ;

Cahill, Daniel P. ;

Santagata, Sandro ;

Brastianos, Priscilla K. .

PHARMACOLOGY & THERAPEUTICS, 2017, 170 :64-72

[3] First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK plus ) NSCLC: A Randomized, Phase 3 Study (ASCEND-4) [J].

De Castro, Gilberto, Jr. ;

Tan, Daniel Shao-Weng ;

Crino, Lucio ;

Wu, Yi Long ;

Paz-Ares, Luis ;

Wolf, Juergen ;

Geater, Sarayut ;

Orlov, Sergey ;

Cortinovis, Diego ;

Yu, Chong-Jen ;

Hochmair, Maximilian ;

Cortot, Alexis ;

Tsai, Chun-Ming ;

Moro-Sibilot, Denis ;

Campelo, Rosario Garcia ;

Branle, Fabrice ;

Sen, Paramita ;

Mcculloch, Tracey ;

Soria, Jean-Charles .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S7-S7

[4] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

[5] Estimating Survival in Patients With Lung Cancer and Brain Metastases An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) [J].

Sperduto, Paul W. ;

Yang, T. Jonathan ;

Beal, Kathryn ;

Pan, Hubert ;

Brown, Paul D. ;

Bangdiwala, Ananta ;

Shanley, Ryan ;

Yeh, Norman ;

Gaspar, Laurie E. ;

Braunstein, Steve ;

Sneed, Penny ;

Boyle, John ;

Kirkpatrick, John P. ;

Mak, Kimberley S. ;

Shih, Helen A. ;

Engelman, Alex ;

Roberge, David ;

Arvold, Nils D. ;

Alexander, Brian ;

Awad, Mark M. ;

Contessa, Joseph ;

Chiang, Veronica ;

Hardie, John ;

Ma, Daniel ;

Lou, Emil ;

Sperduto, William ;

Mehta, Minesh P. .

JAMA ONCOLOGY, 2017, 3 (06) :827-831

[6] Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803) [J].

Wu, Y. -L. ;

Zhou, C. ;

Cheng, Y. ;

Lu, S. ;

Chen, G. -Y. ;

Huang, C. ;

Huang, Y. -S. ;

Yan, H. -H. ;

Ren, S. ;

Liu, Y. ;

Yang, J. -J. .

ANNALS OF ONCOLOGY, 2013, 24 (04) :993-999

[7] BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201) [J].

Wu, Yi Long ;

Yang, Jin-Ji ;

Zhou, Caicun ;

Feng, Jifeng ;

Lu, Shun ;

Song, Yong ;

Huang, Cheng ;

Wu, Gang ;

Cheng, Ying ;

Zhang, Li ;

Hu, Chengping ;

Chen, Gongyan ;

Zhang, Li ;

Liu, Xiaoqing ;

Yan, Hong-Hong ;

Tan, Fenlai ;

Huang, Yi-Sheng .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S6-S6

← 1 →